The in vitro activity of uperin 3.6, alone or combined with six antibiotics, against gram-positive cocci, including Rhodococcus equi, methicillin-resistant staphylococci, and vancomycin-resistant enterococci, was investigated. All isolates were inhibited at concentrations of 1 to 16 mg/liter. Synergy was demonstrated when uperin 3.6 was combined with clarithromycin and doxycycline.
Overuse of antibiotics and failure to apply basic infection control policies and procedures have contributed to the increasing multidrug resistance of many nosocomial pathogens (4, 9, 14) . It represents a serious clinical problem and has created a need for the development of new antimicrobial agents to treat these infections. With the appearance of methicillin-resistant (MR) and vancomycin-resistant (VR) grampositive pathogens, the need for different therapeutic agents is greatly increased, and it has become critical to identify effective agents to treat multidrug-resistant gram-positive infections with novel mechanisms of activity (4, 12, 13, 14, 16, 20) .
During the past decade, a large number of antimicrobial peptides from different organisms have been isolated and characterized (1, 2, 10, 11, 17, 19) . One major area of targeted research has been the skin secretions from amphibians, which have yielded a rich variety of bioactive molecules. The struc-tural diversity of polypeptides secreted from amphibian dermal granular glands is probably reflective of a plethora of different biological functions, including the regulation of skin physiology, defense against predators, or prevention of skin colonization/infection by microorganisms (1) . Of particular note has been the focused effort, during the last decade, of several studies which have reported the host defense peptides exuded in secretions from dorsal glands of some 20 species of Australian anurans, including species from the genera Litoria and Uperoleia (3, 5, 18) . Uperin 3.6 is a wide-spectrum antibiotic peptide isolated from the Australian toadlet Uperoleia mjobergii. With only 17 amino acid residues, uperin 3.6 is smaller than most other wide-spectrum antibiotic peptides isolated from amphibians. In 50% trifluoroethanol, it adopts a well-defined amphipathic alpha helix with distinct hydrophilic and hydrophobic faces. Examination of the activities of synthetic modi- fications of uperin 3.6 reveals that the three lysine residues are essential for antibiotic activity. Uperin 3.6 is one of the most potent membrane-active antimicrobial peptides isolated from amphibians. It adopts an amphipathic ␣-helical structure along its entire length with no central region of enhanced flexibility, a feature commonly found in cationic peptides (3, 5, 18) .
The aim of the present study was to evaluate the in vitro activity of uperin 3.6 and its bactericidal effect for a large number of gram-positive cocci, including Rhodococcus equi, methicillin-resistant staphylococci, and vancomycin-resistant enterococci, as well as to investigate its in vitro interaction with five clinically used antibiotics.
Organisms. The quality control strains included methicillinsusceptible (MS) Staphylococcus aureus ATCC 29213, MR S. aureus ATCC 43300, vancomycin-susceptible (VS) Enterococcus faecalis ATCC 29212, VR E. faecalis ATCC 51299, R. equi ATCC 6939, and Streptococcus pyogenes ATCC 19615. Twenty nosocomial isolates of each species were tested with the exception of VR E. faecalis (12 isolates) and R. equi (12 isolates). The isolates were obtained from distinct immunocompromised patients coming from central Italy and admitted to the Hospital Umberto I, Ancona, Italy. Identification of the strains was performed according to standard procedures. The identification was confirmed by means of the API-Strep and API-Staph systems (bioMérieux Italia, Italy). The different API codes and susceptibility patterns stated the independence of all isolates.
Antimicrobial agents. Uperin 3.6 (Gly-Val-Ile-Asp-Ala-Ala-Lys-Lys-Val-Val-Asn-Val-Leu-Lys-Asn-Leu-Phe-NH 2 ) was synthesized by Fmoc (9-fluorenylmethoxycarbonyl) solid-phase chemistry by the Faculty of Pharmacy, Medical University of Gdańsk, Gdańsk, Poland (7) . The peptide was purified by high-pressure liquid chromatography on a Knauer K501 twopump system and analyzed by chemical analysis, namely, matrix-assisted laser desorption ionization-time of flight mass spectrometry.
Vancomycin and doxycycline (Sigma-Aldrich, Milan, Italy), imipenem (Merck, Sharp & Dohme, Milan, Italy), clarithromycin (Abbott, Rome, Italy), quinupristin-dalfopristin (Aventis Pharma, S.p.A., Lainate, Milan, Italy), and linezolid (Pharmacia S.p.A., Milan, Italy) were tested as control agents.
MIC and MBC determinations. MICs and minimum bactericidal concentrations (MBCs) were assayed according to the procedures outlined by the Clinical and Laboratory Standards Institute (formerly NCCLS) (15) . The ATCC strains mentioned above were used as controls. Experiments were performed in triplicate.
Bacterial killing assay. The ATCC control strains were used to study the in vitro killing effect of uperin 3.6. Aliquots of exponentially growing bacteria were resuspended in fresh Mueller-Hinton broth at approximately 10 7 cells/ml and exposed to uperin 3.6 at 2ϫ MIC for 0, 5, 10, 15, 20, 25, 30, 40, 50, and 60 min at 37°C. After these times, samples were serially diluted in 10 mM of sodium HEPES buffer (pH 7.2) to minimize the carryover effect and plated onto Mueller-Hinton agar plates to obtain viable colonies (8) .
Synergy studies. Table 1 . Killing by uperin 3.6 was rapid, and its activity on staphylococci was complete after a 30-min exposure period at a concentration of 2ϫ MIC, its activities on R. equi and enterococci were complete after 40 min, and its activity on S. pyogenes ATCC 19615 was complete after 10 min at the same concentration (Fig. 1) .
In the combination studies, synergy was observed only for a combination of uperin 3.6 and doxycycline or clarithromycin. (Table 2) .
Overall, our data showed that most of the antimicrobials tested were more active than uperin 3.6 for each genus. Nevertheless, uperin 3.6 was equally active against both susceptible and multiresistant clinical isolates. Of interest, our data showed that although uperin 3.6 was less active than control agents against R. equi isolates, it exhibited MBCs greatly lower than those of other agents. This finding could be very interesting in consideration of the fact that, despite the good in vitro activities of traditional antibiotics, therapy is often partially effective, and relapses occur during the course of the disease. Moreover, time-kill studies have shown a rapid bactericidal effect even if the inactivation of E. faecalis and R. equi appears to be slower than that observed for the other gram-positive cocci.
Combination studies showed that uperin 3.6 acted synergistically with hydrophobic antibiotics, although these data were obtained by using a limited number of isolates. The antimicrobial activities of macrolides and tetracyclines result from their ability to inhibit protein synthesis by binding to the transpeptidation site of the larger ribosomal subunit. Uperin 3.6 has an overall charge of 3ϩ; for this reason, it would be able to interact electrostatically more strongly with anionic phospholipids of the bacterial cell wall. Nevertheless, the lack of flexibility in its central region may be able to compensate this inability and to define its antimicrobial activity profile (3) . The interaction between peptides and macrolides or tetracycline has not yet been extensively studied, and the mechanism of this synergism is unknown at present. However, several reasons may explain this phenomenon. It is probable that the membrane damage induced by the peptide can allow entry of hydrophobic substrates (17) . Uperin 3.6 might increase the access of the hydrophobic antibiotics to the cytoplasmic membrane following breakdown of peptidoglycan, while on the other hand, it is possible that hydrophobic antibiotics create new sites in the biological membranes for peptide entry. Although there is little disagreement over the importance of electrostatic interactions in initiating membrane association of cationic peptides, as well as their selective toxicities toward microorganisms, opinions with regard to the subsequent events that eventually lead to the lysis of microbes differ. Most cationic peptides kill microorganisms by directly permeabilizing and lysing cell membranes, although some are thought to inhibit synthesis of DNA, RNA, and cellular proteins and to insert themselves into cytoplasmic membrane, triggering the activity of bacterial murein hydrolases and leading to degradation of the peptidoglycan with lysis of the cell.
The good antimicrobial activities, as well as the synergistic interactions with hydrophobic antibiotics, suggest uperin 3.6 as a promising candidate for potential application in the treatment of gram-positive bacterial infections. Further in vivo studies are required to validate these results. 
